Angel Physicians Fund

Alphyn Biologics is a life science company focused on developing innovative drug therapies for skin diseases, particularly severe and common skin infections. The company's primary target is infections caused by drug-resistant bacteria, specifically methicillin-resistant Staphylococcus aureus (MRSA). Utilizing its proprietary Multi-Target Therapeutic (MTT) platform, Alphyn Biologics creates topical treatments derived from a tropical plant known for its natural antibacterial properties. This approach aims to address shortcomings in existing treatments, such as efficacy, side effects, and patient tolerability, ultimately providing a safe and effective solution for patients suffering from bacterial skin infections.

PanTher Therapeutics is a biotechnology company developing cancer drug-delivery technologies. Its core platform enables therapeutics to be delivered directly to the tumor site, reducing systemic toxicity and allowing higher drug concentrations at the target while enabling sustained treatment. This approach aims to improve therapeutic efficacy and outcomes for hard-to-treat cancers by maximizing drug exposure at the tumor while limiting exposure to healthy tissue. Headquartered in Cambridge, Massachusetts, PanTher Therapeutics is advancing investigational candidates, including a lead program in pancreatic cancer, to broaden the potential of precision delivery in oncology.

Based in Boston's biotech hub, Elucid improves cardiovascular diagnostic imaging via machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software for evaluating plaque vulnerability from a single CT scan to inform risk assessment and treatment selection.

Founded in 2017, S4 Medical specializes in developing medical devices for cardiac procedures. Its flagship product is a device designed to protect the esophagus during catheter ablation treatments for atrial fibrillation.

Moray Medical is a company focused on developing innovative robotic delivery systems for structural heart therapies, specifically targeting edge-to-edge valve leaflet repair. The company aims to enhance the quality of life for millions affected by leaky heart valves by providing cardiologists with advanced tools for mitral valve clip therapies. Moray Medical's proprietary microfluidic robotics technology enables the precise and safe delivery of treatments, utilizing a compact, reusable fluid-drive system that features a digital interface for maneuvering flexible delivery catheters with ease, akin to using a computer cursor. This approach allows for cost-effective interventions, making life-saving heart valve therapies more accessible to a broader range of patients in need.

Founded in 2013, Foldax designs and manufactures synthetic heart valves using life polymer technology. Its products aim to provide artificial blood pumping support for patients with aortic, mitral, or tricuspid valve disease via percutaneous or surgical delivery.